AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2390157 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextrose (25g)
Number of subjects: 0
Study 7011331 — intervention group
Group type: EXPERIMENTAL
Intervention: Org GC 94 (3 x 5 mg/day for 3 months)
Number of subjects: 60
Study 7011331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 x 0.5 mg or placebo daily)
Number of subjects: 60
Study 31564020 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen
Number of subjects: 71
Study 31564020 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 71
Study 31564020 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 71
Study 30209682 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% NaOCl and 18% HEBP
Number of subjects: 100
Study 30209682 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 100
Study 30209682 — intervention group
Group type: COMPARATOR
Intervention: 6% NaOCl
Number of subjects: 100
Study 30209682 — intervention group
Group type: COMPARATOR
Intervention: 17% EDTA
Number of subjects: 100
Study 30209682 — intervention group
Group type: COMPARATOR
Intervention: 18% HEBP
Number of subjects: 100
Study 29553543 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal autologous graft by Limoli Retinal Restoration Technique (LRRT) in group A (11 eyes).
Number of subjects: 25
Study 29553543 — intervention group
Group type: COMPARATOR
Intervention: Control group B (14 eyes) with no intervention.
Number of subjects: 25
Study 27270119 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with splinting
Number of subjects: 181
Study 27270119 — intervention group
Group type: COMPARATOR
Intervention: Splinting alone
Number of subjects: 181
Study 24568365 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon nitride cage
Number of subjects: 100
Study 24568365 — intervention group
Group type: COMPARATOR
Intervention: PEEK cage
Number of subjects: 100
Study 22270502 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine
Number of subjects: 60
Study 22270502 — intervention group
Group type: COMPARATOR
Intervention: 4% liposomal lidocaine
Number of subjects: 60
Study 20976217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (IPTp‐SP)
Number of subjects: 0
Study 16333818 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 16
Study 16117182 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine and L-arginine (3 g each/day) for 10 days
Number of subjects: 29
Study 16117182 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 29
Study 12407644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin, 2,500 U
Number of subjects: 21
Study 12407644 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin, 40 mg
Number of subjects: 21
Study 12407644 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid, 34 U/kg
Number of subjects: 21
Study 9773701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nalbuphine 60 microg/kg/h
Number of subjects: 75
Study 9773701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous naloxone 2 microg/kg/h
Number of subjects: 75
Study 9773701 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline infusion only
Number of subjects: 75
Study 7812025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent treatment with 5‐ASA tablets (2.4 g for the first week of each month)
Number of subjects: 50
Study 7812025 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with 5‐ASA tablets (1.6 g each day)
Number of subjects: 50
Study 3166357 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (12 1-g capsules daily)
Number of subjects: 18
Study 3166357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (safflower oil)
Number of subjects: 18
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting prognosis of IgAN
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary protein excretion (1‐3.5 g/d)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary protein excretion (≥ 3.5 g/d)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR (G2)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR (G3)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR (G4)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR (G5)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperuricaemia
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesangial proliferation
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental glomerulosclerosis
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular atrophy/interstitial fibrosis (T1)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular atrophy/interstitial fibrosis (T2)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Crescents (C1)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Crescents (C2)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerulosclerosis (25‐49%)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerulosclerosis (≥ 50%)
Number of subjects: 869
Study 29743598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram C-index
Number of subjects: 869
Study 27138027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 45 mg in subjects with varying degrees of renal impairment (study 1)
Number of subjects: 64
Study 27138027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 15 mg in subjects with normal hepatic function or moderate hepatic impairment (study 2)
Number of subjects: 64
Study 24417608 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 66
Study 24417608 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 66
Study 22365820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of oxytocin (OT)
Number of subjects: 14
Study 22365820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19796703 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (socially evaluated cold pressor test)
Number of subjects: 48
Study 19796703 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 48
Study 19031757 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modification
Number of subjects: 78
Study 19031757 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus a supervised structured exercise program for 6 weeks (SE)
Number of subjects: 78
Study 19031757 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus a supervised structured exercise program for 1 year (CE)
Number of subjects: 78
Study 15897717 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (4 units/day for men; 3 units/day for women)
Number of subjects: 19
Study 15897717 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free beer (4 units/day for men; 3 units/day for women)
Number of subjects: 19
Study 15342612 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (initial dose of 10 mg/kg within 6 hours after birth, followed by two 5 mg/kg doses at 24-hour intervals)
Number of subjects: 62
Study 15342612 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative ibuprofen (same dosage regimen as prophylactic)
Number of subjects: 62
Study 15342612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12515150 — intervention group
Group type: EXPERIMENTAL
Intervention: milrinone
Number of subjects: 30
Study 12515150 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 9059186 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin (group 1)
Number of subjects: 63
Study 9059186 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (group 2)
Number of subjects: 63
Study 9059186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 8299455 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin injected subcutaneously in the abdomen
Number of subjects: 22
Study 8299455 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH and regular insulins injected subcutaneously in the abdomen
Number of subjects: 22
Study 8299455 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin injected subcutaneously in the thigh
Number of subjects: 22
Study 8299455 — intervention group
Group type: COMPARATOR
Intervention: NPH and regular insulins injected subcutaneously in the thigh
Number of subjects: 22
Study 2868645 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 71
Study 2868645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 2604052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen sedation for 90 minutes followed by 100% oxygen for 2 minutes
Number of subjects: 12
Study 2604052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen sedation for 90 minutes followed by 10 minutes of 100% oxygen
Number of subjects: 12
Study 2604052 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen for 90 minutes
Number of subjects: 12
Study 2604052 — intervention group
Group type: COMPARATOR
Intervention: Room air for 90 minutes (baseline)
Number of subjects: 12
Study 2604052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scale measurement for self-evaluation of alertness
Number of subjects: 12
Study 29952663 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 60
Study 29952663 — intervention group
Group type: EXPERIMENTAL
Intervention: Lataz
Number of subjects: 60
Study 29952663 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalaprost
Number of subjects: 60
Study 31813614 — intervention group
Group type: EXPERIMENTAL
Intervention: On-Idebenone (900 mg/day)
Number of subjects: 18
Study 29953297 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ounce of an exogenous BHB solution (KETO)
Number of subjects: 10
Study 29953297 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric placebo (CON)
Number of subjects: 10
Study 28854283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine (9.5 mg daily)
Number of subjects: 29
Study 28854283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (400 mg twice daily, titrated progressively)
Number of subjects: 29
Study 28854283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no new medication)
Number of subjects: 29
Study 28854283 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rivastigmine
Number of subjects: 29
Study 26044234 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stent with high-pressure balloon inflation (Group A)
Number of subjects: 167
Study 26044234 — intervention group
Group type: COMPARATOR
Intervention: Single stent with high- and low-pressure balloon inflation at proximal and distal segment (Group B)
Number of subjects: 167
Study 23680517 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture (Quill; Angiotech Pharmaceuticals, Inc.)
Number of subjects: 63
Study 23680517 — intervention group
Group type: COMPARATOR
Intervention: Standard suture (Vicryl; Ethicon Inc.)
Number of subjects: 63
Study 21733822 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg bid for 6 months)
Number of subjects: 137
Study 21733822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 21733822 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 137
Study 21733822 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ratio of COX‐2 to 15‐hydroxyprostaglandin dehydrogenase mRNA in BAL cells
Number of subjects: 137
Study 18696173 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination resistance and balance-jumping training (COMB)
Number of subjects: 149
Study 16914029 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids and/or long-acting beta-2-agonists
Number of subjects: 416
Study 16914029 — intervention group
Group type: COMPARATOR
Intervention: No treatment (neither inhaled corticosteroids nor long-acting beta-2-agonists)
Number of subjects: 416
Study 16914029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 416
Study 16914029 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age, low FEV1, lower health status
Number of subjects: 416
Study 15514271 — intervention group
Group type: EXPERIMENTAL
Intervention: (58)FeSO(4) + Na(2)EDTA
Number of subjects: 53
Study 15514271 — intervention group
Group type: COMPARATOR
Intervention: (58)FeSO(4)
Number of subjects: 53
Study 11712080 — intervention group
Group type: EXPERIMENTAL
Intervention: Comic film
Number of subjects: 21
Study 11712080 — intervention group
Group type: COMPARATOR
Intervention: Control film
Number of subjects: 21
Study 9203100 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE barrier membrane
Number of subjects: 10
Study 9203100 — intervention group
Group type: COMPARATOR
Intervention: Conventional control
Number of subjects: 10
Study 8425035 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 8425035 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-trimester screening for Down syndrome
Number of subjects: 0
Study 8425035 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of renal damage in fetuses with obstructive uropathy
Number of subjects: 0
Study 8425035 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-to-twin transfusion syndrome
Number of subjects: 0
Study 2959924 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (oral, sustained-release)
Number of subjects: 10
Study 29878183 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable successful aging dimensions in vignettes
Number of subjects: 2010
Study 29878183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 2010
Study 29878183 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 2010
Study 29878183 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease
Number of subjects: 2010
Study 29878183 — intervention group
Group type: EXPERIMENTAL
Intervention: Productive engagement
Number of subjects: 2010
Study 29878183 — intervention group
Group type: EXPERIMENTAL
Intervention: Older respondents
Number of subjects: 2010
Study 28506741 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbished two-bed ICU patient room with a new suspended wall-to-wall ceiling and a low frequency absorber
Number of subjects: 31
Study 28506741 — intervention group
Group type: COMPARATOR
Intervention: Identical two-bed room (control) remained unchanged
Number of subjects: 31
Study 28969697 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching combined with light therapy and pulsed electromagnetic field therapy
Number of subjects: 96
Study 28969697 — intervention group
Group type: COMPARATOR
Intervention: Coaching with the device turned off (Placebo group)
Number of subjects: 96
Study 28969697 — intervention group
Group type: COMPARATOR
Intervention: Coaching only (Control group)
Number of subjects: 96
Study 26370187 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (400 mg, twice daily)
Number of subjects: 417
Study 26370187 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 417
Study 26370187 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 417
Study 24217238 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction with reduced maintenance immunosuppression
Number of subjects: 20
Study 21752453 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal doses of buserelin acetate (5 μg) with varying sperm counts (6, 12, 24, 50, and 100 million total sperm in 0.5 mL)
Number of subjects: 751
Study 21752453 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal plasma dilutions (1/4 and 1/20) with 5 μg of buserelin acetate
Number of subjects: 751
Study 21752453 — intervention group
Group type: COMPARATOR
Intervention: 1 μg of buserelin acetate administered intramuscularly
Number of subjects: 751
Study 18251609 — intervention group
Group type: EXPERIMENTAL
Intervention: CO(2) laser therapy
Number of subjects: 90
Study 18251609 — intervention group
Group type: COMPARATOR
Intervention: Nonirradiated control
Number of subjects: 90
Study 16955427 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (treatment)
Number of subjects: 44
Study 16955427 — intervention group
Group type: EXPERIMENTAL
Intervention: CSDD mood subscale (treatment)
Number of subjects: 44
Study 16955427 — intervention group
Group type: EXPERIMENTAL
Intervention: HDRS (treatment)
Number of subjects: 44
Study 16955427 — intervention group
Group type: EXPERIMENTAL
Intervention: NPI-M (treatment)
Number of subjects: 44
Study 16955427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 44
Study 14671530 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic pump placed in the subacromial space
Number of subjects: 0
Study 14671530 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic pump placed in the glenohumeral joint
Number of subjects: 0
Study 14671530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10811042 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP rapid test
Number of subjects: 812
Study 10811042 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CRP test)
Number of subjects: 812
Study 8874332 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 125 mg/m2 over 24 hours followed by doxorubicin 48 mg/m2 over 48 hours
Number of subjects: 10
Study 8874332 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 48 mg/m2 over 48 hours followed by paclitaxel 125 mg/m2 over 24 hours
Number of subjects: 10
Study 8874332 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-doxorubicin sequence
Number of subjects: 10
Study 8874332 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-paclitaxel sequence
Number of subjects: 10
Study 1989806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Intralipid infusion (500 ml, 20 percent, infused over 5 hours)
Number of subjects: 0
Study 1989806 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Intralipid infusion (500 ml, 20 percent, infused over 10 hours)
Number of subjects: 0
Study 1989806 — intervention group
Group type: COMPARATOR
Intervention: Both fast and slow Intralipid infusion
Number of subjects: 0
Study 6135433 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 4
Study 6135433 — intervention group
Group type: EXPERIMENTAL
Intervention: minaxolone
Number of subjects: 4
Study 6135433 — intervention group
Group type: EXPERIMENTAL
Intervention: di-isopropyl phenol
Number of subjects: 4
Study 6135433 — intervention group
Group type: COMPARATOR
Intervention: halothane
Number of subjects: 4
Study 30882162 — intervention group
Group type: COMPARATOR
Intervention: Cleansing of the perianal skin using povidone‐iodine cotton balls (Group I, n=165)
Number of subjects: 451
Study 30882162 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of povidone‐iodine solution (0.1 g/mL) into the anal and lower rectal canals (Group II, n=116)
Number of subjects: 451
Study 30882162 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct manual cleansing of the mucosal surface of the anus and lower rectum using povidone‐iodine cotton balls (Group III, n=170)
Number of subjects: 451
Study 30739745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (target systolic blood pressure 130-140 mm Hg within 1 h)
Number of subjects: 2196
Study 30739745 — intervention group
Group type: COMPARATOR
Intervention: Guideline blood pressure lowering (target systolic blood pressure <180 mm Hg)
Number of subjects: 2196
Study 30739745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 2196
Study 30739745 — intervention group
Group type: COMPARATOR
Intervention: Guideline blood pressure lowering
Number of subjects: 2196
Study 29266839 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day 1-L polyethylene glycol (1-L PEG)
Number of subjects: 44
Study 29266839 — intervention group
Group type: COMPARATOR
Intervention: Split-dose 4-L polyethylene glycol (4-L PEG)
Number of subjects: 44
Study 26465792 — intervention group
Group type: EXPERIMENTAL
Intervention: LYM-X-SORB™ (LXS)
Number of subjects: 110
Study 26465792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25004921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 120
Study 25004921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 120
Study 25004921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg/kg
Number of subjects: 120
Study 25004921 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control group)
Number of subjects: 120
Study 22339553 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical product for night-time application aimed at adipolysis and microcirculation stimulation
Number of subjects: 100
Study 22339553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20596066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on traditional Chinese medicine
Number of subjects: 30
Study 20596066 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 18265875 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal helminth infection
Number of subjects: 387
Study 18265875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild eosinophilia
Number of subjects: 387
Study 18265875 — intervention group
Group type: EXPERIMENTAL
Intervention: Marked eosinophilia
Number of subjects: 387
Study 16111418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone digital images
Number of subjects: 14
Study 16111418 — intervention group
Group type: COMPARATOR
Intervention: Conventional X‐ray box
Number of subjects: 14